Recent News

Siemens Healthineers to Acquire Epocal from Alere to Complete Its Blood Gas Portfolio

NORWOOD, Mass., July 21, 2017 (BUSINESS WIRE) Siemens Healthineers has entered into a definitive agreement to acquire Epocal Inc., a subsidiary of Alere Inc. Epocal Inc. develops and provides point-of-care blood diagnostic systems for healthcare enterprises, including the epocĀ® Blood Analysis System, a handheld, wireless testing solution. Financial details of the transaction are not being disclosed...

View Full Article
Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treat

HAMILTON, ON, February 23, 2017 - Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson & Johnson Innovation - JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital...

View Full Article
Profound Medical Announces Appointment of Kenneth Galbraith to its Board of Directors

TORONTO, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate care, today announced the appointment of Kenneth Galbraith to its Board of Directors.

View Full Article
Invitae announces new leadership structure to drive global growth

January 09, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, today announced that Sean George, Ph.D., its co-founder and current president and chief operating officer, has been named chief executive officer for the company.

View Full Article
Invitae meets annual volume guidance, projects doubling of volume in 2017, accelerates Genome Network by acquiring scala

January 06, 2017 - Invitae Corporation (https://www.invitae.com/en) (NYSE:NVTA), one of the fastest growing genetic information companies, announced initial fourth quarter and full-year 2016 results, showing 200% year-over-year growth in billable test volume, driven by milestones including a major expansion of its test menu to more than 1,100 genes and agreements...

View Full Article
Invitae Announces Pricing of Public Offering of Common Stock

November 17, 2016 - SAN FRANCISCO -- (BUSINESS WIRE) -- Invitae Corporation (NYSE:NVTA) today announced the pricing of an underwritten public offering of 7,333,333 shares of its common stock at a price to the public of $6.00 per share.

View Full Article
Profound Medical Corp. Completes Previously Announced $17.4 Million Bought Deal Offering of Common Shares

TORONTO, Nov. 14, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. ("Profound" or the "Company") (TSX-V:PRN) today announced that it has completed its previously announced bought deal offering of 15,820,000 common shares of the Company ("Common Shares") at a price of $1.10 per Common Share (the "Offering") for gross proceeds of...

View Full Article
Profound Medical Corp Announces First Patient Treated in TACT Pivotal Clinical Trial at Venderbilt University Medical Ce

TORONTO, Sept, 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company") a medical device company focused on prostate care, today announced that the first patient has been treated in the TACT Pivotal Clinical Trial at Vanderbilt University Medical Center in Nashville, TN.

View Full Article
Profound Medical Corp. Announces Senior Management Changes to Support Global Growth Strategy

TORONTO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) ("Profound" or the "Company"), an emerging medical device company focused on prostate cancer care, today announced the appointment of Arun Menawat, Ph.D. as its new Chief Executive Officer.

View Full Article
Aptinyx Initiates Dosing in Phase 1 Clinical Study of Lead NMDA-Receptor Modulator, NYX-2925

Evanston, Ill., July 13, 2016 - Aptinyx Inc., a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurologic disorders, today announced the initiation of dosing in a Phase 1, first-in-human study for its lead therapeutic candidate, NYX 2925. 

View Full Article
Profound Medical Corp. and Philips Sign Sales and Marketing Agreement in MRI-guided therapy for prostate cancer

TORONTO and AMSTERDAM, Netherlands, May 11, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN), a Toronto-based medical device company and Royal Philips (NYSE:PHG) (AEX:PHIA), a leading health technology company, today announced that they have signed a sales and marketing agreement that will advance the commercial launch of Profound's TULSA-PRO, a minimally...

View Full Article